A Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb BVS
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2018
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ABSORB UK
- Sponsors Abbott Vascular
- 13 Dec 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 09 Jan 2018 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.